UNITED STATES WELDING INC
PharmaUNITED STATES WELDING INC is a pharmaceutical company with 1 FDA-approved products.
UNITED STATES WELDING INC at a Glance
- Fast trial execution (30 months median completion)
UNITED STATES WELDING INC's Key Drugs
UNITED STATES WELDING INC's core commercial portfolio centers on MEDICAL AIR, USP — its most strategically important drugs approved in the last 15 years.
UNITED STATES WELDING INC's Recent FDA Approvals
UNITED STATES WELDING INC secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
UNITED STATES WELDING INC's Therapeutic Areas
Disease areas where UNITED STATES WELDING INC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
UNITED STATES WELDING INC Pipeline Snapshot
Active clinical trials for UNITED STATES WELDING INC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • MEDICAL AIR, USP leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 7/20 completed
- • Speed: 30 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2013-08-31
- Latest
- 2013-08-31
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges